Nilufer Yigit

Dr. Nilufer Yigit

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2025 in Seminars in Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
PDF file
GAGoksel Altinisik
Goksel Altinisik
NYNilufer Yigit
Nilufer Yigit
NCNazli Cetin
Nazli Cetin
Pulmonary alveolar microlithiasis (PAM) has been well characterized in terms of its description, genetic background, and diagnostic process for decades; however, no effective prevention or treatment has yet been established. PAM is classified as an ultrarare lung disease linked to mutations in the autosomal recessive sodium–phosphate co-transporter gene SLC34A2, which may serve as a potential target for future therapies. As new variants of SLC34A2 mutations continue to be identified, a broader genetic understanding could help predict the variable clinical course among patients and guide the development of therapies beyond palliative care. The creation of a disease severity score would be valuable for assessing disease burden, stratifying patients, and designing research studies. Given the clinico-radiological dissociation and heterogeneity of PAM, such a score should be developed as a composite index. Coupled with objective severity measures and identification of factors underlying individual variability, this approach could enhance insight into preventive and therapeutic strategies. Clinical advances in PAM remain limited, underscoring the need for international registries and cohorts as an urgent priority. Systematic re-evaluation of diagnosed cases and structured follow-up, rather than arbitrary visits, would generate standardized data critical for future research. A standardized patient evaluation form may facilitate the collection of data in a shared database.

30 December 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
FUFirdevs Ulutaş
Firdevs Ulutaş
GAGoksel Altinisik
Goksel Altinisik
GGGülay Güngör
Gülay Güngör
VÇVefa Çakmak
Vefa Çakmak
NYNilufer Yigit
Nilufer Yigit
VÇVeli Çobankara
Veli Çobankara
Background/Objective: In recent years, artificial intelligence (AI) has gained increasing prominence in the fields of diagnostic decision-making in medicine. The aim of this study was to compare multidisciplinary team (MDT: rheumatology, pulmonology, thoracic radiology) decisions with single-session plans generated by ChatGPT-4o. Methods: In this cross-sectional concordance study, adults (≥18 years) with confirmed systemic autoimmune rheumatic disease (SARD) and having MDT decisions within the last 6 months were included. The study documented diagnostic, treatment, and monitoring decisions in cases of SARDs by recording answers to six essential questions: (1) What is the most likely clinical diagnosis? (2) What is the most likely radiological diagnosis? (3) Is there a need for anti-inflammatory treatment? (4) Is there a need for antifibrotic treatment? (5) Is drug-free follow-up appropriate? and (6) Are additional investigations required? Consequently, all evaluations were performed with ChatGPT-4o in a single-session format using a standardized single-prompt template, with the system blinded to MDT decisions. All data analyses in this study were conducted using the R programming language (version 4.3.2). An agreement between AI-generated and MDT decisions was assessed using Cohen’s Kappa (κ) statistic where κ (kappa) values represent the level of agreement: 0.80 = almost perfect agreement. These analyses were performed using the irr and psych packages in R. Statistical significance of the models was evaluated through p-values, while overall model fit was assessed using the Likelihood Ratio Test. Results: A total of 47 patients were involved in this study, with a predominance of female patients (61.70%, n = 29). The mean age was 61.74 ± 10.40 years. The most frequently observed diagnosis was rheumatoid arthritis (RA), accounting for 31.91% of cases (n = 15). This was followed by cases of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, interstitial pneumonia with autoimmune features (IPAF), and sarcoidosis. The analyses indicate a statistically significant level of agreement across all decision types. For clinical diagnosis decisions, agreement was moderate (κ = 0.52), suggesting that the AI system can reach partially consistent conclusions in diagnostic processes. The need for an immunosuppressive treatment and follow-up without medication decisions demonstrated a higher level of concordance, reaching the moderate-to-high range (κ = 0.64 and κ = 0.67, respectively). For antifibrotic treatment decisions, agreement was moderate (κ = 0.49), while radiological diagnosis decisions also fell within the moderate range (κ = 0.55). The lowest agreement—though still moderate—was observed in further investigation required decisions (κ = 0.45). Conclusions: In patients with SARDs with pulmonary involvement, particularly in complex cases, concordance was observed between MDT decisions and AI-generated recommendations regarding prioritization of clinical and radiologic diagnoses, treatment selection, suitability for drug-free follow-up, and the need for further diagnostic investigations.

2 June 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
NYNilufer Yigit
Nilufer Yigit
EUErhan Uğurlu
Erhan Uğurlu
MSMeryem Sanlıalp
Meryem Sanlıalp
EKEmel Kılıçarslan
Emel Kılıçarslan
İAİlknur Hatice Akbudak
İlknur Hatice Akbudak
HŞHande Şenol
Hande Şenol
Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the standard minimally invasive technique for mediastinal lymph node sampling; however, its diagnostic performance is limited in diseases requiring preserved tissue architecture, such as lymphoma and granulomatous disorders. EBUS-guided transbronchial mediastinal cryobiopsy (EBUS-TBMC) has emerged as a technique capable of obtaining larger, histologically intact samples. Evidence comparing these modalities in isolated mediastinal lymphadenopathy is limited. Methods: In this prospective, single-center, head-to-head cohort study, 89 consecutive patients with isolated mediastinal lymphadenopathy without parenchymal lung masses were enrolled. All patients underwent sequential EBUS-TBNA followed by EBUS-TBMC within the same session. The primary outcome was diagnostic yield; secondary outcomes included tissue adequacy and procedure-related complications. Results: EBUS-TBMC demonstrated a significantly higher diagnostic yield than EBUS-TBNA (83.1% vs. 28.0%, p < 0.001). TBMC established a diagnosis in 74/89 patients, whereas TBNA was diagnostic in 25/89. TBMC provided an additional diagnosis in 49 patients with non-diagnostic TBNA, while no case was diagnosed exclusively by TBNA. Superiority was consistent across malignant and benign conditions, particularly lymphoma and granulomatous diseases. Diagnostic yield was higher when ≥3 cryobiopsy samples were obtained (86.6% vs. 42.8%). Bleeding events were more frequent with TBMC but were mild-to-moderate, managed bronchoscopically, and no major complications or life-threatening events occurred. Conclusions: In isolated, mass-negative mediastinal lymphadenopathy, EBUS-TBMC provides a substantially higher diagnostic yield than TBNA. Early integration of TBMC may improve diagnostic efficiency and reduce the need for repeat or surgical procedures.

10 January 2024 in Thoracic Research and Practice
Verified
Journal Article
Open access
ABAyşe Baha
Ayşe Baha
NKNurdan Kokturk
Nurdan Kokturk
CBCaner Baysan
Caner Baysan
BÖBurcu Öztürk
Burcu Öztürk
SCSümeyye Kodalak Cengiz
Sümeyye Kodalak Cengiz
AAAylin Ozgen Alpaydin
Aylin Ozgen Alpaydin
COPD,severe exacerbation,costs,discharge,antibiotic,nutrition,pulmonary rehabilitation

27 January 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
FUFirdevs Ulutaş
Firdevs Ulutaş
KKKürşat Kaya
Kürşat Kaya
NYNilufer Yigit
Nilufer Yigit
VÇVeli Çobankara
Veli Çobankara
Background/Objectives: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) represents one of the major contributors to morbidity and mortality in Rheumatoid arthritis (RA), yet its underlying molecular mechanisms remain incompletely defined. Activin A, a member of the transforming growth factor-β (TGF-β) superfamily, has emerged as a key regulator of inflammation, fibroblast activation, and tissue remodeling. However, its role in RA patients with interstitial lung disease (ILD) has not been fully elucidated. We aimed to investigate circulating levels of Activin A, Follistatin-Like Protein-1 (FSTL1), and Follistatin-Like Protein-3 (FSTL3) in patients with RA, RA-ILD, idiopathic pulmonary fibrosis (IPF), and healthy controls and explore their associations with disease activity and pulmonary function parameters. Methods: This cross-sectional study included 90 participants: healthy controls (n = 20), RA (n = 25), RA-ILD (n = 21), and IPF (n = 24). Serum biomarkers were quantified using validated enzyme-linked immunosorbent assays (ELISAs). Clinical characteristics, inflammatory markers, disease activity indices, and pulmonary function tests were recorded. Group comparisons and correlation analyses were performed using appropriate parametric and non-parametric statistical methods. Results: Circulating Activin A levels were progressively increased from controls to RA, RA-ILD, and IPF, with significantly higher concentrations in all disease groups relative to controls. FSTL1 levels were significantly reduced in RA-ILD patients compared with RA and controls, while FSTL3 levels were markedly elevated in IPF. Activin A did not correlate with disease activity indices or pulmonary function parameters, whereas FSTL1 correlated positively with diffusing capacity of the lungs for carbon monoxide and disease duration, and FSTL3 showed an inverse association with lactate dehydrogenase. Conclusions: Activin A may be associated with the fibroinflammatory burden in both RA-ILD and IPF. The observation of altered circulating levels of Follistatin-like proteins—key regulatory molecules with multifaceted biological functions—suggests that the underlying pathogenesis is complex and governed by tightly regulated, interconnected signaling pathways.

25 March 2026 in Tuberk Toraks
Verified
Journal Article
Closed access
NYNilufer Yigit
Nilufer Yigit
HAHilal Argüner
Hilal Argüner
SBSevin Başer
Sevin Başer
HŞHande Şenol
Hande Şenol
GDGamze Gokoz Dogu
Gamze Gokoz Dogu
AGAziz Gültekin
Aziz Gültekin
Lung adenocarcinoma is a heterogeneous malignancy characterized by diverse molecular profiles that influence prognosis and treatment response. Identifying noninvasive imaging biomarkers capable of predicting genetic alterations may support early diagnosis and facilitate personalized therapeutic strategies. In this retrospective study, 225 patients with lung adenocarcinoma who underwent baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging and molecular mutation testing were evaluated. Tumor metabolic activity was quantified using the maximum standardized uptake value (SUVmax) of the primary lesion. The relationship between SUVmax and molecular alterations, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 receptor tyrosine kinase (ROS1), Kirsten rat sarcoma viral oncogene homolog mutations, and programmed deathligand 1 (PD-L1) expression, was analyzed. EGFR mutation-positive tumors demonstrated significantly lower SUVmax values compared with mutation-negative tumors. In contrast, PD-L1- positive tumors were associated with higher SUVmax values. No significant correlation was identified between SUVmax and ALK or ROS1 alterations. Tumor metabolic activity measured by PET/CT may reflect specific molecular characteristics of lung adenocarcinoma. PET/CT-derived metabolic parameters, particularly when integrated with artificial intelligence and radiomics, could serve as non-invasive predictors of molecular alterations and help guide individualized treatment strategies. Prospective multicenter studies are warranted to validate these findings and confirm their clinical applicability.